Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Centre for Statistics in Medicine

Professor Gary Collins awarded prestigious NIHR Senior Investigator award

NDORMS Professor of Medical Statistics and Director of the Centre for Statistics in Medicine, Gary Collins has been appointed National Institute of Health Research (NIHR) Senior Investigator.

COVID jab linked to lower risk of COVID-19-related clot and heart complications

NDORMS research shows that vaccination reduced the risk of heart failure and some clot-related complications for up to a year.

Removing bias from healthcare AI tools

Rapid advances in Artificial Intelligence (AI) have opened the way for the creation of a huge range of new healthcare tools, but to ensure that these tools do not exacerbate preexisting health inequities, researchers urge the use of more representative data in their development.

New reporting guideline will provide transparency in consensus research

Published in PLOS, the new guideline will help the scientific community to write complete and transparent research reports involving consensus methods.

COVID-19 vaccines found effective in reducing long COVID symptoms

A recent study has revealed the effectiveness of COVID-19 vaccines in preventing long COVID.

Fair safe medical AI: a South Asia case study to co-develop local agency & trust leaving no one behind

The Planetary Health Informatics Lab led by Associate Professor Sara Khalid at NDORMS has announced that it is a winner of a Global Grand Challenges award – an initiative fostering innovation to solve pressing global health and development problems and funded by the Bill & Melinda Gates Foundation.

Jonathan Cook made Professor of Clinical Trials and Medical Statistics

Jonathan Cook was successful in the 2023 University Recognition of Distinction exercise

Researchers call for urgent action in hip fracture prevention

An international group of researchers, including Prof. Daniel Prieto-Alhambra at NDORMS, have predicted that hip fracture burden will nearly double worldwide by 2050

DARWIN EU® success leads to expansion

The European Medicines Agency (EMA) initiative DARWIN EU® has completed its first studies and is calling for new data partners

Data-Driven research will map COVID-19 vaccine effectiveness in Brazil and Pakistan

A study to monitor the safety and effectiveness of the COVID-19 vaccine in the Global South, has received funding from the Bill & Melinda Gates Foundation’s Grand Challenges initiative.

Jonathan Cook elected as Society for Clinical Trials board member

Associate Professor Jonathan Cook has been elected to the Society for Clinical Trials (SCT) board.

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

New cost-benefit model of Fracture Liaison Services helping healthcare decision makers

The newly developed model to estimate the health benefits and budget impact of Fracture Liaison Services (FLS) finds them highly effective in shaping positive patient outcomes, and will help drive policy decisions.

Sara Khalid named Associate Professor at NDORMS

The University of Oxford has awarded the title of Associate Professor to Dr Sara Khalid as part of its recognition of excellence awards.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

Daniel Prieto-Alhambra receives ISPE award for COVID-19 research

Daniel Prieto-Alhambra has been awarded the 'Special ISPE award for contributions to public health associated with the COVID-19 pandemic.'

Junqing Xie awarded by the International Society for Pharmacoepidemiology

Congratulations to Junqing (Frank) Xie who has been awarded the Stanley A. Edlavitch Award from The International Society for Pharmacoepidemiology (ISPE).

Higher risk of blood clots in COVID-19 outpatients, largely reduced after vaccination

Researchers at NDORMS have studied the association between ambulatory COVID-19 and short-term risk of venal thrombosis and the clinical and genetic risk factors predisposing them to developing post–COVID-19 thrombosis.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Rethinking pain management after injury

NDORMS researchers are to study whether a pain management treatment using cognitive behavioural therapy will improve recovery for people who have had a major leg injury.

Oxford leads global cross-collaboration Covid research

A new collaboration between Oxford, Brazil and Pakistan has been funded by the Bill & Melinda Gates Foundation. The partnership will provide researchers with de-identified health data from two of the worlds global COVID-19 hotspots to increase understanding of COVID-19 in these communities and help accelerate the management of the disease.

NDORMS joins DARWIN EU® Coordination Centre for drug and vaccine safety

The European Medicines Agency has announced the establishment of the Data Analysis and Real World Interrogation Network (DARWIN EU®) to support better decision making on the development and effectiveness of medicines and vaccines.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

New advanced analytics research to deliver next level of insights into COVID-19

NDORMS is leading one of nine new studies awarded total of £2m to use large-scale linked data to address priority research questions that will improve understanding of the pandemic and inform the continued policy response.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

COVID-19 vaccine safety monitoring should account for age, gender, and database differences

The largest, most extensive global network study on background rates for adverse events of special interest identifies important age, sex and database differences that should inform future safety surveillance efforts.

Professor Dani Prieto-Alhambra elected to ISPE Board of Directors

Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, has been elected as the Academic representative for Europe and Africa on the International Society of Pharmaco-Epidemiology Board of Directors.

3,400 different medicines used globally to treat COVID-19

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study

Understanding the first wave of COVID-19 and implications for tackling the ongoing pandemic: evidence from 5.5 million people from Catalonia, Spain

Health outcomes during the first wave of COVID-19 in Catalonia, Spain, have been described in detail in a study published by Nature Communications.

Patients set to benefit from new guidelines on Artificial Intelligence health solutions

Patients could benefit from a faster and more effective introduction of artificial intelligence (AI) innovations to diagnose and treat disease – thanks to the first international standards for reporting of clinical trials for AI.

Grant towards OHDSI Global Research on COVID-19 treatments

An international cohort of OHDSI collaborators obtain a grant from the COVID-19 Therapeutics Accelerator to lead an effort to compare the effectiveness of treatments, including corticosteroids such as dexamethasone, under current evaluation for COVID-19 across an international observational data network.

Six-month outcomes after treatment for COVID-19 on intensive care units in England

Researchers at the University of Oxford are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care.

Patients with rheumatic pain increasingly turning to opioids

Reporting at EULAR, researchers found that opioid use by patients with rheumatic and musculoskeletal pain was on the rise in Europe.

Could do better: clinical trial reporting fails to live up to the mark

The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary primary endpoint requires substantial improvement, suggests NDORMS research published in BMC Medicine.

COVID-19 prognosis and prediction models for medical decision-making are flawed, say researchers

The modelling and approach to tackle the hard medical decisions associated with the spread of the COVID-19 virus may be based on weak and overly-optimistic evidence from studies that are biased and unreliable, suggests research published by The BMJ today.

Oxford-led research describes the safety profile and potential harms of hydroxychloroquine and azithromycin

Over 300 international researchers from the Observational Health Data Sciences and Informatics (OHDSI) community studied data from almost 1 million patients. They declared hydroxychloroquine safe for short-term use, but urge caution in using it in combination with azithromycin.

Sponsored place available for the Randomised Controlled Trials Course

The inaugural Doug Altman scholarship will be offered to an LMIC (lower-to-middle-income country) applicant or a student.

Flu antiviral has bigger benefits for sicker, older patients

A Europe-wide study conducted over three flu seasons finds that the antiviral drug, oseltamivir (Tamiflu®), can help people recover from flu-like illness about one-day sooner on average, with older, sicker patients who have been unwell for longer recovering two-to-three days sooner.

NIHR success for NDORMS researchers

Four investigators based at the Botnar Research Centre, NDORMS have been recently awarded National Institute for Health Research (NIHR) fellowships to further our understanding of a variety of musculoskeletal conditions and develop better methodology to support medical research.

How do you explain your research to the public?

... Spend a day at a science festival talking to children! Patricia Logullo talks about her experience at Cheltenham Science Festival.

Mounting evidence that BMI and smoking should not be used for rationing knee and hip replacement

A new study by researchers at NDORMS, University of Oxford now published in Osteoarthritis and Cartilage found that the average lifetime risk of needing further surgery following knee and hip replacement – revision surgery – was around 5% after knee replacement and 8% after hip replacement, with neither body mass index (BMI, combining an individual's height and weight) or smoking having any meaningful effect on these risks.